These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The difference in mechanism of action of 5-fluorouracil and its nucleosides in L5178y cells. Yoshida M, Hoshi A, Kuretani K. J Pharmacobiodyn; 1980 Aug; 3(8):374-9. PubMed ID: 6451683 [Abstract] [Full Text] [Related]
8. Irreversible cytotoxic effect of a novel lowly immunosuppressive antitumor fluorouridine derivative, UK-21. Mori H, Nakayama K, Ishida R, Ito S, Nagai H, Koda A. Anticancer Drugs; 1997 Jun; 8(5):482-8. PubMed ID: 9215612 [Abstract] [Full Text] [Related]
9. Comparison of 5-fluoro-2'-deoxyuridine and 5-fluorouracil in the treatment of murine colon cancer; effects on thymidylate synthase. van der Wilt CL, van Laar JA, Smid K, Rustum YM, Peters GJ. Adv Exp Med Biol; 1994 Jun; 370():109-14. PubMed ID: 7660870 [No Abstract] [Full Text] [Related]
10. Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate. Nakajima Y, Iigo M, Hoshi A. Anticancer Drugs; 1992 Jun; 3(3):289-92. PubMed ID: 1525410 [Abstract] [Full Text] [Related]
11. Dual modulation by l-leucovorin and recombinant human interferon alpha 2a of 5-fluorouracil antitumor activity against the human colon carcinoma xenograft Co-4. Kase S, Kubota T, Watanabe M, Furukawa T, Tanino H, Kuo TH, Saikawa Y, Teramoto T, Kitajima M. J Interferon Cytokine Res; 1995 Dec; 15(12):1089-93. PubMed ID: 8746791 [Abstract] [Full Text] [Related]
12. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. Lorenz M, Müller HH. J Clin Oncol; 2000 Jan; 18(2):243-54. PubMed ID: 10637236 [Abstract] [Full Text] [Related]
14. Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes. Peters GJ, Braakhuis BJ, de Bruijn EA, Laurensse EJ, van Walsum M, Pinedo HM. Br J Cancer; 1989 Mar; 59(3):327-34. PubMed ID: 2522792 [Abstract] [Full Text] [Related]
15. Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of antitumor activity with dosage and FUra incorporation into RNA. Nord LD, Stolfi RL, Martin DS. Biochem Pharmacol; 1992 Jun 23; 43(12):2543-9. PubMed ID: 1378737 [Abstract] [Full Text] [Related]
16. 5-Fluorouracil and derivatives in cancer chemotherapy. 3. In vivo enhancement of antitumor activity of 5-fluorouracil (FU) and 5-fluoro-2'-deoxyuridine (FUDR). Jato J, Windheuser JJ. J Pharm Sci; 1973 Dec 23; 62(12):1975-8. PubMed ID: 4271579 [No Abstract] [Full Text] [Related]
20. Enzymatic conversion of 5-fluoro-2'-deoxyuridine to 5-fluorouracil or 5-fluoro-2'-deoxyuridine 5'-monophosphate in human tissues. Uchida M, Brown N, Ho DH. Anticancer Res; 1990 Dec 23; 10(3):779-83. PubMed ID: 2142396 [Abstract] [Full Text] [Related] Page: [Next] [New Search]